Fertigyn HP: Precision hCG for Advanced Hormone Therapy
| Product dosage: 10000iu | |||
|---|---|---|---|
| Package (num) | Per ampoule | Price | Buy |
| 3 | $28.42 | $85.25 (0%) | 🛒 Add to cart |
| 5 | $26.08
Best per ampoule | $142.09 $130.39 (8%) | 🛒 Add to cart |
| Product dosage: 2000iu | |||
|---|---|---|---|
| Package (num) | Per ampoule | Price | Buy |
| 3 | $16.72 | $50.15 (0%) | 🛒 Add to cart |
| 5 | $15.04
Best per ampoule | $83.58 $75.22 (10%) | 🛒 Add to cart |
| Product dosage: 5000iu | |||
|---|---|---|---|
| Package (num) | Per ampoule | Price | Buy |
| 3 | $18.39 | $55.16 (0%) | 🛒 Add to cart |
| 5 | $17.05
Best per ampoule | $91.94 $85.25 (7%) | 🛒 Add to cart |
Fertigyn HP (Human Chorionic Gonadotropin) represents a significant advancement in pharmaceutical-grade hormone therapy, specifically engineered for medical professionals requiring exact dosing control and reliable biological activity. This highly purified formulation delivers consistent luteinizing hormone (LH) mimicry with minimal batch-to-batch variability, making it an indispensable tool in reproductive medicine and endocrine regulation. Manufactured under stringent quality control protocols, Fertigyn HP ensures optimal stability and bioavailability, providing clinicians with a trusted agent for triggering ovulation, treating hypogonadism, and supporting specialized therapeutic protocols. Its high purity profile reduces the risk of immunogenic reactions, making it suitable for both acute interventions and long-term treatment plans.
Features
- Highly purified human chorionic gonadotropin (hCG) extracted from natural sources
- Precisely calibrated potency: 5000 IU and 10,000 IU formulations available
- Lyophilized powder form for enhanced stability and extended shelf life
- Packaged with bacteriostatic water for precise reconstitution
- Single-dose vials with rubber stoppers for aseptic withdrawal
- Manufactured in compliance with cGMP and international pharmacopeia standards
- Low endotoxin levels (<0.1 EU/IU) confirmed through LAL testing
- HPLC and mass spectrometry verified molecular integrity
- pH-balanced formulation for minimal injection discomfort
- Tamper-evident packaging with lot number tracking
Benefits
- Precise Ovulation Induction: Enables accurate timing of follicular maturation and rupture for assisted reproductive technology (ART) cycles
- Testosterone Stimulation: Effectively triggers Leydig cell production of endogenous testosterone in hypogonadal males
- Reduced Immunogenicity: High purification process minimizes antibody formation risk during extended therapy
- Consistent Biological Response: Standardized potency ensures predictable clinical outcomes across patient populations
- Flexible Dosing Protocols: Multiple strength options allow customization for individual patient needs and treatment phases
- Improved Treatment Adherence: Minimal side effect profile and reliable efficacy support long-term therapy compliance
Common use
Fertigyn HP is primarily employed in clinical settings for the management of endocrine and reproductive disorders. In female patients, it is indicated for triggering final follicular maturation and luteinization in women undergoing ovulation induction as part of ART protocols, particularly following follicular development with gonadotropins. In male patients, it is utilized for the treatment of prepubertal cryptorchidism not due to anatomical obstruction and for stimulating testosterone production in hypogonadotropic hypogonadism. Off-label applications include combination therapy with human menopausal gonadotropin (hMG) for spermatogenesis induction and adjunct use in weight management programs under strict medical supervision.
Dosage and direction
For ovulation induction: 5,000–10,000 IU administered as a single intramuscular injection once follicular maturation is confirmed via ultrasound and estradiol levels. Administration typically occurs 24–48 hours after the last dose of gonadotropin medication.
For hypogonadotropic hypogonadism: 1,000–4,000 IU administered 2–3 times weekly via intramuscular injection for 3–6 weeks, followed by maintenance therapy at 2,000 IU twice weekly. Dosage must be titrated based on testosterone response.
For cryptorchidism: 1,000–5,000 IU administered 2–3 times weekly for up to 8 weeks via intramuscular injection. Surgical evaluation required if no descent occurs.
Reconstitute with provided bacteriostatic water: gently swirl until clear solution forms. Do not shake vigorously. Administer immediately after reconstitution. Rotate injection sites to prevent lipoatrophy.
Precautions
- Strict aseptic technique must be maintained during reconstitution and administration to prevent microbial contamination
- Regular ultrasound monitoring of ovarian response is mandatory during ovulation induction to prevent ovarian hyperstimulation syndrome (OHSS)
- Testosterone levels should be monitored periodically in males to avoid supraphysiological concentrations
- Use with caution in patients with history of epilepsy, migraine, or asthma due to potential fluid retention effects
- Cardiovascular status should be evaluated in patients with cardiac or renal impairment due to possible edema
- May impair ability to drive or operate machinery due to potential dizziness or visual disturbances
- Not recommended for patients with hormone-sensitive cancers unless benefits outweigh risks
Contraindications
- Known hypersensitivity to human chorionic gonadotropin or any component of the formulation
- Prior anaphylactic reaction to gonadotropin preparations
- Uncontrolled thyroid or adrenal dysfunction
- Organic intracranial lesions such as pituitary tumors
- Premature puberty in males
- Ovarian cyst or enlargement not due to polycystic ovarian syndrome
- Abnormal uterine bleeding of undetermined etiology
- Prostate carcinoma or other androgen-dependent neoplasms
Possible side effect
Common (≥1/100): Injection site reactions (erythema, swelling, pain), headache, fatigue, irritability, restlessness
Less common (≥1/1000): Mild ovarian hyperstimulation symptoms (abdominal distension, discomfort), gynecomastia in males, acne, increased libido
Rare (<1/1000): Severe ovarian hyperstimulation syndrome (ascites, pleural effusion, hemoconcentration), thromboembolic events, precocious puberty in children, anaphylactoid reactions
Post-marketing reports: Ectopic pregnancy, ovarian torsion, antibody formation with prolonged use, visual disturbances, depression
Drug interaction
- Concomitant use with gonadotropins (FSH, LH) may potentiate ovarian response and increase OHSS risk
- Corticosteroids may enhance fluid retention effects
- Testosterone replacement therapy may lead to additive androgen effects
- Aromatase inhibitors may alter estrogen production in response to hCG
- Anticoagulants: theoretical increased thrombotic risk requires monitoring
- Insulin and oral hypoglycemics: hCG may affect glucose tolerance requiring adjustment
- Thyroid medications: hCG has weak TSH-like activity that may affect requirements
Missed dose
If a scheduled dose is missed, administer as soon as remembered unless it is near the time for the next scheduled dose. Do not double the dose to make up for a missed administration. For ovulation induction protocols, contact the treating physician immediately as timing is critical. For chronic therapy, resume the regular dosing schedule. Document the occurrence in the patient’s medical record and assess potential impact on treatment efficacy.
Overdose
Overdose may manifest as severe ovarian hyperstimulation syndrome in women (characterized by rapid weight gain, abdominal pain, nausea, vomiting, oliguria, and respiratory distress) or excessive androgen effects in men (including aggressive behavior, severe acne, and excessive virilization). There is no specific antidote. Treatment is supportive and symptomatic: hospitalization for severe OHSS with fluid/electrolyte management, thromboprophylaxis, and paracentesis if indicated. Androgen effects in males typically resolve with discontinuation. Dialysis is not effective due to large molecular size.
Storage
Store unopened vials at 2–8°C in original packaging protected from light. Do not freeze. Reconstituted solution is stable for 30 days when refrigerated at 2–8°C, but should ideally be used immediately. Discard any solution that appears cloudy or contains particulate matter. Keep out of reach of children. Do not use beyond the expiration date printed on packaging. Transport under refrigerated conditions when necessary.
Disclaimer
This information is intended for healthcare professionals only. Fertigyn HP is a prescription medication that must be used under appropriate medical supervision. The prescribing physician should be familiar with gonadotropin therapy and manage treatment based on individual patient assessment. Full prescribing information including detailed warnings, precautions, and adverse reactions should be consulted before administration. Not all possible uses, interactions, or adverse effects are described herein.
Reviews
“Fertigyn HP has become our standard hCG preparation for ART cycles due to its consistent potency and reliable ovulation trigger response. We’ve observed improved cycle coordination and reduced cancellation rates compared to other preparations.” - Reproductive Endocrinologist, Madrid
“In my andrology practice, the predictable testosterone response with Fertigyn HP has allowed for better titration in hypogonadal patients. The high purity reduces injection site reactions that we previously encountered with other brands.” - Andrologist, Berlin
“The batch-to-batch consistency is remarkable. We’ve used over 50 vials in our weight management clinic (under IRB protocol) and have observed minimal variability in biological effect across patients.” - Research Endocrinologist, London
“As a pharmacy specializing in compounded hormone therapies, we appreciate the rigorous quality control documentation provided with each lot. This level of transparency is essential for patient safety.” - Chief Pharmacist, Amsterdam